- Home
- ARQT
as 02-21-2025 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Upcoming Earnings Alert:
Get ready for potential market movements as Arcutis Biotherapeutics Inc. ARQT prepares to release earnings report on 25 Feb 2025.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $17.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.99 - $16.20 | Next Earning Date: | 02-25-2025 |
| Revenue: | $138,708,000 | Revenue Growth: | 182.84% |
| Revenue Growth (this year): | 217.37% | Revenue Growth (next year): | 55.64% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Matsuda Masaru | ARQT | See Remarks | Feb 3 '25 | Sell | $12.70 | 8,338 | $105,892.60 | 178,692 | |
| Burnett Patrick | ARQT | See Remarks | Feb 3 '25 | Sell | $12.70 | 12,116 | $153,873.20 | 114,862 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Feb 3 '25 | Sell | $12.70 | 19,301 | $245,122.70 | 804,129 | |
| Edwards Larry Todd | ARQT | See Remarks | Feb 3 '25 | Sell | $12.70 | 2,173 | $27,597.10 | 135,555 | |
| Welgus Howard G. | ARQT | Director | Jan 2 '25 | Sell | $14.67 | 10,000 | $146,714.00 | 151,944 | |
| Burnett Patrick | ARQT | See Remarks | Dec 31 '24 | Sell | $14.00 | 1,691 | $23,674.00 | 114,862 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Dec 20 '24 | Sell | $15.17 | 15,000 | $227,566.50 | 804,129 | |
| Welgus Howard G. | ARQT | Director | Dec 2 '24 | Sell | $12.51 | 10,000 | $125,133.00 | 151,944 | |
| Edwards Larry Todd | ARQT | See Remarks | Nov 30 '24 | Buy | $7.11 | 1,093 | $7,766.86 | 137,728 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
GlobeNewswire
3 days ago
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
Zacks
5 days ago
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet
Simply Wall St.
5 days ago
High Growth Tech Stocks To Watch In February 2025
Zacks
8 days ago
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Zacks
9 days ago
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?
Zacks
11 days ago
Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher
Investor's Business Daily
16 days ago
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.